Implications of thyroid hormones (TH) in rexinoids anti-lymphoma activity: integrin alpha V Beta 3 inhibition in the treatment of T cell lymphoma (TCL) with bexarotene

JOHANNA DIAZ ALBUJA; CINTHIA ROSEMBLIT; GRACIELA A CREMASCHI; MARIA M DEBERNARDI; MARIA CELESTE DIAZ FLAQUE MC; LEANDRO CERCHIETTI; HELENA A STERLE; ALEJANDRA PAULAZO; MARIA FLORENCIA CAYROL

Mar del Plata

Congreso; Reunion Conjunta SAIC, SAFE, SAB, SAP; 2019

Bexarotene (Bex), a RXR agonist used for cutaneous TLC treatment, is associated with clinical hypothyroidism, thus requiring the concomitant administration of levothyroxine (T4). We found that physiological levels of TH contribute to the malignant phenotype of TCL via the TH membrane receptor (mTR), the integrin V3. Here we investigated the consequence of T4 on the antineoplastic effect of Bex in different TCL subtypes.We confirm the presence of the RXR by WB in our panel of TCL subtypes. Bex effect in vitro on apoptosis and proliferation of CUTLL1, OCI-Ly12 and OCI- Ly13.2 TCL cells was higher in the absence than in the presence of TH supplementation (p